Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: A department of veterans affairs cooperative study

D. O. Clegg, D. J. Reda, E. Mejias, G. W. Cannon, M. H. Weisman, T. Taylor, E. Budiman-Mak, W. D. Blackburn, F. B. Vasey, M. L. Mahowald, J. J. Cush, H. R. Schumacher, S. L. Silverman, F. P. Alepa, M. E. Luggen, M. R. Cohen, R. Makkena, C. M. Haakenson, R. H. Ward, B. J. ManasterR. J. Anderson, J. R. Ward, W. G. Henderson

Research output: Contribution to journalArticle

Abstract

Objective. To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective for the treatment of active psoriatic arthritis (PsA) resistant to nonsteroidal antiinflammatory drug therapy. Methods. Two hundred twenty-one patients with PsA were recruited from 15 clinics, randomized (double-blind) to SSZ or placebo treatment, and followed up for 36 weeks. Treatment response was based on joint pain/tenderness and swelling scores and physician and patient global assessments. Results. Longitudinal analysis revealed a trend favoring SSZ treatment (P = 0.13). At the end of treatment, response rates were 57.8% for SSZ compared with 44.6% for placebo (P = 0.05). The Westergren erythrocyte sedimentation rate declined more in the PsA patients taking SSZ than in those taking placebo (P < 0.0001). Adverse reactions were fewer than expected and were mainly due to nonspecific gastrointestinal complaints, including dyspepsia, nausea, vomiting, and diarrhea. Conclusion. SSZ at a dosage of 2,000 mg/day is well tolerated and may be more effective than placebo in the treatment of patients with PsA.

Original languageEnglish (US)
Pages (from-to)2013-2020
Number of pages8
JournalArthritis and Rheumatism
Volume39
Issue number12
DOIs
StatePublished - 1996
Externally publishedYes

Fingerprint

Sulfasalazine
Psoriatic Arthritis
Veterans
Placebos
Therapeutics
Dyspepsia
Blood Sedimentation
Arthralgia
Nausea
Vomiting
Diarrhea
Anti-Inflammatory Agents
Physicians
Drug Therapy

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Clegg, D. O., Reda, D. J., Mejias, E., Cannon, G. W., Weisman, M. H., Taylor, T., ... Henderson, W. G. (1996). Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: A department of veterans affairs cooperative study. Arthritis and Rheumatism, 39(12), 2013-2020. https://doi.org/10.1002/art.1780391210

Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis : A department of veterans affairs cooperative study. / Clegg, D. O.; Reda, D. J.; Mejias, E.; Cannon, G. W.; Weisman, M. H.; Taylor, T.; Budiman-Mak, E.; Blackburn, W. D.; Vasey, F. B.; Mahowald, M. L.; Cush, J. J.; Schumacher, H. R.; Silverman, S. L.; Alepa, F. P.; Luggen, M. E.; Cohen, M. R.; Makkena, R.; Haakenson, C. M.; Ward, R. H.; Manaster, B. J.; Anderson, R. J.; Ward, J. R.; Henderson, W. G.

In: Arthritis and Rheumatism, Vol. 39, No. 12, 1996, p. 2013-2020.

Research output: Contribution to journalArticle

Clegg, DO, Reda, DJ, Mejias, E, Cannon, GW, Weisman, MH, Taylor, T, Budiman-Mak, E, Blackburn, WD, Vasey, FB, Mahowald, ML, Cush, JJ, Schumacher, HR, Silverman, SL, Alepa, FP, Luggen, ME, Cohen, MR, Makkena, R, Haakenson, CM, Ward, RH, Manaster, BJ, Anderson, RJ, Ward, JR & Henderson, WG 1996, 'Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: A department of veterans affairs cooperative study', Arthritis and Rheumatism, vol. 39, no. 12, pp. 2013-2020. https://doi.org/10.1002/art.1780391210
Clegg, D. O. ; Reda, D. J. ; Mejias, E. ; Cannon, G. W. ; Weisman, M. H. ; Taylor, T. ; Budiman-Mak, E. ; Blackburn, W. D. ; Vasey, F. B. ; Mahowald, M. L. ; Cush, J. J. ; Schumacher, H. R. ; Silverman, S. L. ; Alepa, F. P. ; Luggen, M. E. ; Cohen, M. R. ; Makkena, R. ; Haakenson, C. M. ; Ward, R. H. ; Manaster, B. J. ; Anderson, R. J. ; Ward, J. R. ; Henderson, W. G. / Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis : A department of veterans affairs cooperative study. In: Arthritis and Rheumatism. 1996 ; Vol. 39, No. 12. pp. 2013-2020.
@article{f5fc4d8679a04cf29a1c647936a76d4a,
title = "Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: A department of veterans affairs cooperative study",
abstract = "Objective. To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective for the treatment of active psoriatic arthritis (PsA) resistant to nonsteroidal antiinflammatory drug therapy. Methods. Two hundred twenty-one patients with PsA were recruited from 15 clinics, randomized (double-blind) to SSZ or placebo treatment, and followed up for 36 weeks. Treatment response was based on joint pain/tenderness and swelling scores and physician and patient global assessments. Results. Longitudinal analysis revealed a trend favoring SSZ treatment (P = 0.13). At the end of treatment, response rates were 57.8{\%} for SSZ compared with 44.6{\%} for placebo (P = 0.05). The Westergren erythrocyte sedimentation rate declined more in the PsA patients taking SSZ than in those taking placebo (P < 0.0001). Adverse reactions were fewer than expected and were mainly due to nonspecific gastrointestinal complaints, including dyspepsia, nausea, vomiting, and diarrhea. Conclusion. SSZ at a dosage of 2,000 mg/day is well tolerated and may be more effective than placebo in the treatment of patients with PsA.",
author = "Clegg, {D. O.} and Reda, {D. J.} and E. Mejias and Cannon, {G. W.} and Weisman, {M. H.} and T. Taylor and E. Budiman-Mak and Blackburn, {W. D.} and Vasey, {F. B.} and Mahowald, {M. L.} and Cush, {J. J.} and Schumacher, {H. R.} and Silverman, {S. L.} and Alepa, {F. P.} and Luggen, {M. E.} and Cohen, {M. R.} and R. Makkena and Haakenson, {C. M.} and Ward, {R. H.} and Manaster, {B. J.} and Anderson, {R. J.} and Ward, {J. R.} and Henderson, {W. G.}",
year = "1996",
doi = "10.1002/art.1780391210",
language = "English (US)",
volume = "39",
pages = "2013--2020",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "12",

}

TY - JOUR

T1 - Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis

T2 - A department of veterans affairs cooperative study

AU - Clegg, D. O.

AU - Reda, D. J.

AU - Mejias, E.

AU - Cannon, G. W.

AU - Weisman, M. H.

AU - Taylor, T.

AU - Budiman-Mak, E.

AU - Blackburn, W. D.

AU - Vasey, F. B.

AU - Mahowald, M. L.

AU - Cush, J. J.

AU - Schumacher, H. R.

AU - Silverman, S. L.

AU - Alepa, F. P.

AU - Luggen, M. E.

AU - Cohen, M. R.

AU - Makkena, R.

AU - Haakenson, C. M.

AU - Ward, R. H.

AU - Manaster, B. J.

AU - Anderson, R. J.

AU - Ward, J. R.

AU - Henderson, W. G.

PY - 1996

Y1 - 1996

N2 - Objective. To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective for the treatment of active psoriatic arthritis (PsA) resistant to nonsteroidal antiinflammatory drug therapy. Methods. Two hundred twenty-one patients with PsA were recruited from 15 clinics, randomized (double-blind) to SSZ or placebo treatment, and followed up for 36 weeks. Treatment response was based on joint pain/tenderness and swelling scores and physician and patient global assessments. Results. Longitudinal analysis revealed a trend favoring SSZ treatment (P = 0.13). At the end of treatment, response rates were 57.8% for SSZ compared with 44.6% for placebo (P = 0.05). The Westergren erythrocyte sedimentation rate declined more in the PsA patients taking SSZ than in those taking placebo (P < 0.0001). Adverse reactions were fewer than expected and were mainly due to nonspecific gastrointestinal complaints, including dyspepsia, nausea, vomiting, and diarrhea. Conclusion. SSZ at a dosage of 2,000 mg/day is well tolerated and may be more effective than placebo in the treatment of patients with PsA.

AB - Objective. To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective for the treatment of active psoriatic arthritis (PsA) resistant to nonsteroidal antiinflammatory drug therapy. Methods. Two hundred twenty-one patients with PsA were recruited from 15 clinics, randomized (double-blind) to SSZ or placebo treatment, and followed up for 36 weeks. Treatment response was based on joint pain/tenderness and swelling scores and physician and patient global assessments. Results. Longitudinal analysis revealed a trend favoring SSZ treatment (P = 0.13). At the end of treatment, response rates were 57.8% for SSZ compared with 44.6% for placebo (P = 0.05). The Westergren erythrocyte sedimentation rate declined more in the PsA patients taking SSZ than in those taking placebo (P < 0.0001). Adverse reactions were fewer than expected and were mainly due to nonspecific gastrointestinal complaints, including dyspepsia, nausea, vomiting, and diarrhea. Conclusion. SSZ at a dosage of 2,000 mg/day is well tolerated and may be more effective than placebo in the treatment of patients with PsA.

UR - http://www.scopus.com/inward/record.url?scp=2042519830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2042519830&partnerID=8YFLogxK

U2 - 10.1002/art.1780391210

DO - 10.1002/art.1780391210

M3 - Article

C2 - 8961906

AN - SCOPUS:2042519830

VL - 39

SP - 2013

EP - 2020

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 12

ER -